Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19190
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMbeutcha, Aurélie-
dc.contributor.authorRoupret, Morgan-
dc.contributor.authorKamat, Ashish M-
dc.contributor.authorKarakiewicz, Pierre I-
dc.contributor.authorLawrentschuk, Nathan-
dc.contributor.authorNovara, Giacomo-
dc.contributor.authorRaman, Jay D-
dc.contributor.authorSeitz, Christian-
dc.contributor.authorXylinas, Evanguelos-
dc.contributor.authorShariat, Shahrokh F-
dc.date2016-04-21-
dc.date.accessioned2018-09-13T00:21:10Z-
dc.date.available2018-09-13T00:21:10Z-
dc.date.issued2017-03-
dc.identifier.citationWorld Journal of Urology 2017; 35(3): 337-353-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/19190-
dc.description.abstractUpper tract urothelial carcinoma (UTUC) is a rare and heterogeneous disease. Several clinical and biological prognostic factors have been identified in multi-institutional collaborative works with the aim of helping decision-making in pursuit of tailored individual patient care. This review provides an overview of these existing prognostic factors and predictive tools for the management of patients with UTUC. A systematic literature search was performed using PubMed/MEDLINE, Web of Science and Scopus databases regarding articles published in English between January 2000 and November 2015 according to PRISMA guidelines. Thresholds of 100 and 300 patients were applied for studies on biomarkers and clinical studies, respectively. All the studies on predictive tools were included for analysis. Outcomes of interest were features associated with advanced-stage UTUC, disease recurrence and survival. A total of 116 studies were included in this review. These large and/or multi-institutional studies have confirmed the prognostic value of standard pathological factors (i.e., tumor stage, grade and lymph node metastasis) and identified novel features such as lymphovascular invasion, tumor architecture, multifocality, concomitant CIS, variant histology and biomarker status among others. Based on these variables, several predictive tools have been developed; however, they often lack of validation. The value of these features and tools needs prospective testing. Efforts provided by international collaboration groups have permitted to validate established features and identify new features of biologically and clinically aggressive UTUC. Further investigation on prognostic factors and biomarkers is still needed to assess the benefit of these features and tools on clinical decision-making.-
dc.language.isoeng-
dc.subjectBiomarkers-
dc.subjectDisease recurrence-
dc.subjectNomograms-
dc.subjectPredictive tools-
dc.subjectPrognosis-
dc.subjectPrognostic factors-
dc.subjectRisk stratification-
dc.subjectSurvival-
dc.subjectUpper tract urothelial carcinoma-
dc.titlePrognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review.-
dc.typeJournal Article-
dc.identifier.journaltitleWorld Journal of Urology-
dc.identifier.affiliationDepartment of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Urology, Cochin Hospital, APHP, Paris Descartes University, Paris, Franceen
dc.identifier.affiliationDepartment of Urology, University of Montreal Health Center, Montreal, QC, Canadaen
dc.identifier.affiliationDepartment of Surgery, Oncology, and Gastroenterology - Urology Clinic, University of Padua, Padua, Italyen
dc.identifier.affiliationDivision of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USAen
dc.identifier.affiliationDepartment of Urology, University of Nice Sophia-Antipolis, Hôpital Pasteur 2, Centre Hospitalier Universitaire de Nice, Nice, Franceen
dc.identifier.affiliationDepartment of Urology, Pitié-Salpétrière Hospital, APHP, University Paris VI, Paris, Franceen
dc.identifier.affiliationDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austriaen
dc.identifier.affiliationDepartment of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USAen
dc.identifier.affiliationDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Währinger Gürtel 18-20, 1090, Vienna, Austriaen
dc.identifier.affiliationDepartment of Urology, Weill Cornell Medical College, New York, NY, USAen
dc.identifier.affiliationDepartment of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USAen
dc.identifier.affiliationDepartment of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1007/s00345-016-1826-2-
dc.identifier.orcid0000-0001-8553-5618-
dc.identifier.pubmedid27101100-
dc.type.austinJournal Article-
dc.type.austinReview-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

4
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.